Department of Biochemistry and Molecular Biology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan, China.
Biosci Trends. 2010 Apr;4(2):39-47.
Hepatitis B induced by hepatitis B virus (HBV) remains a major public health problem worldwide. Although several antiviral drugs have been approved for hepatitis B, they cause significant dose-dependent side-effects (interferon-alpha) and drug resistance (lamivudine, etc.). Safe and potent new anti-HBV drugs are urgently needed. Traditional Chinese medicine (TCM) is an established segment of the health care system in China and widely used for hepatitis B in China and many parts of the world. Many TCMs and related active compounds have been reported that have promising and potent anti-HBV activities, including Phyllanthus, Salvia miltiorrhiza, Rheum palmatum L., Radix Astragali, oxymatrine, artemisinin and artesunate, and wogonin. Thus, TCM is a potential candidate for anti-HBV drugs. More information is needed regarding TCMs, including preparation, standardization, identification of active ingredients, and toxicological evaluation. Therefore, TCM development needs to apply advanced and interdisciplinary methodology and technology and perform further rigorously designed experimental and clinical investigations.
乙型肝炎病毒（HBV）引起的乙型肝炎仍然是全球主要的公共卫生问题。尽管已经批准了几种用于治疗乙型肝炎的抗病毒药物，但它们会引起显著的剂量依赖性副作用（干扰素-α）和耐药性（拉米夫定等）。因此，急需安全有效的新型抗乙型肝炎病毒药物。中药（TCM）是中国医疗保健系统的一个既定部分，在中国和世界许多地方广泛用于治疗乙型肝炎。已有报道称，许多中药和相关的活性化合物具有有前途和有效的抗乙型肝炎病毒活性，包括叶下珠、丹参、大黄、黄芪、氧化苦参碱、青蒿素和青蒿琥酯以及黄岑素。因此，中药是抗乙型肝炎病毒药物的潜在候选药物。需要更多关于中药的信息，包括制剂、标准化、活性成分的鉴定和毒理学评价。因此，中药的发展需要应用先进的跨学科方法和技术，并进行进一步严格设计的实验和临床研究。
